Development of HVJ Envelope Vector and Its Application to Gene Therapy

Area of Science:

• Biotechnology
• Gene Therapy
• Virology

Background:

• Liposomes containing Hemagglutinating Virus of Japan (HVJ) fusion proteins were developed for gene and drug delivery.
• The need for simpler and more efficient gene delivery systems led to the development of non-viral vectors.

Purpose of the Study:

• To develop the HVJ envelope vector, a non-viral vector system derived from HVJ.
• To evaluate the efficiency and applications of the HVJ envelope vector for gene and drug delivery in vitro and in vivo.

Main Methods:

• Inactivated HVJ was used to create the HVJ envelope vector by incorporating exogenous DNA into the viral envelope.
• Detergent treatment and centrifugation were employed in the vector preparation process.
• The HVJ envelope vector's delivery capabilities were tested using cultured cells, animal models, and various therapeutic molecules.

Main Results:

• The HVJ envelope vector demonstrated efficient and rapid delivery of plasmid DNA to cultured cells and organs.
• Proteins, synthetic oligonucleotides, and drugs were successfully introduced into cells using the HVJ envelope vector.
• Therapeutic applications showed success in preventing and treating hearing impairment in rats and cancers in mice through gene transfer.

Conclusions:

• The HVJ envelope vector is a highly efficient and minimally invasive tool for gene and drug delivery.
• This vector system holds significant promise for both ex vivo and in vivo gene therapy applications.
• Commercial-scale production of clinical-grade HVJ envelope vector for human gene therapy is underway.